Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 14, 2009Journal of Clinical OncologyOpen Access

Cost Effectiveness and Screening Interval of Lipid Screening in Hodgkin's Lymphoma Survivors

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does lipid screening improve cost-effectiveness and survival in survivors of Hodgkin's lymphoma who received mediastinal irradiation?

Population

Hypothetical cohort of 30-year-old survivors of Hodgkin's lymphoma who survived 5 years after mediastinal…

Comparison

Lipid screening at 1-, 3-, 5-, or 7-year… vs No screening

Design

Other

Follow-up

Lifetime (modeled)

Authors

ACAileen B. ChenRPRinaa S. PungliaKKKaren M. Kuntz

Discussion

Loading...

Member takes

Overview

May support 3-year lipid screening in irradiated Hodgkin survivors; leaves open randomized confirmation of survival benefit.

Structured PICO

Does lipid screening improve cost-effectiveness and survival in survivors of Hodgkin's lymphoma who received mediastinal irradiation?

P
Population
Hypothetical cohort of 30-year-old survivors of Hodgkin's lymphoma who survived 5 years after mediastinal irradiation
I
Intervention
Lipid screening at 1-, 3-, 5-, or 7-year intervals, with statin therapy for screen-positive patients
C
Comparator
No screening
O
Outcome
Incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) saved

Lipid screening every 3 years in Hodgkin's lymphoma survivors treated with mediastinal irradiation is a cost-effective strategy to improve survival.

Cite This Study

Chen et al. (2009) studied this question.

synapsesocial.com/papers/6a7c316fb7016f3e7d3bdabahttps://doi.org/10.1200/jco.2009.22.8460
View Full Paper
Ask AI
Bookmark
Share